INTRODUCTION: Malignant mesothelioma (MM) is an aggressive disease with limited therapeutic options. In preclinical models, vascular endothelial growth factor (VEGF) stimulates MM proliferation. In MM patients, higher plasma VEGF levels correlate inversely with survival. Cediranib is an orally administered tyrosine kinase inhibitor of VEGF receptors-1, -2, and -3. METHODS: We conducted a multi-center phase II trial of cediranib in patients with unresectable, histologically-confirmed MM who had received ≤1 prior regimen of chemotherapy. The primary endpoint was objective response rate. Initial cediranib dosing was 45 mg daily during a 28-day cycle. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily. RESULTS: Fifty-one patients enrolled at 9 centers; 50 were evaluable for response. Partial responses were observed in 10% of patients; stable disease was seen in 34%. Disease control (PR+SD) was higher at the 45 mg cediranib dose level (67% vs. 34%, p=0.04). Median progression-free survival was 1.8 months (95% CI 0.1, 14.2); median overall survival (OS) was 4.4 months (95% CI 0.9, 41.7). The 1-year survival rate was 15%. Grade 3/4 toxicities were more frequent in the 45 mg dose level group (87% vs. 43%, p=0.002). These included fatigue, hypertension, pulmonary embolism, angioedema, and reversible posterior leukoencephalopathy. Median OS was superior in patients who developed ≥grade 3 hypertension (8.5 vs. 4.1 months, p=0.024). CONCLUSION: This trial did not meet its pre-specified response endpoint. A higher cediranib dose level was associated with improved disease control, but this dose was poorly tolerated.
INTRODUCTION:Malignant mesothelioma (MM) is an aggressive disease with limited therapeutic options. In preclinical models, vascular endothelial growth factor (VEGF) stimulates MM proliferation. In MMpatients, higher plasma VEGF levels correlate inversely with survival. Cediranib is an orally administered tyrosine kinase inhibitor of VEGF receptors-1, -2, and -3. METHODS: We conducted a multi-center phase II trial of cediranib in patients with unresectable, histologically-confirmed MM who had received ≤1 prior regimen of chemotherapy. The primary endpoint was objective response rate. Initial cediranib dosing was 45 mg daily during a 28-day cycle. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily. RESULTS: Fifty-one patients enrolled at 9 centers; 50 were evaluable for response. Partial responses were observed in 10% of patients; stable disease was seen in 34%. Disease control (PR+SD) was higher at the 45 mg cediranib dose level (67% vs. 34%, p=0.04). Median progression-free survival was 1.8 months (95% CI 0.1, 14.2); median overall survival (OS) was 4.4 months (95% CI 0.9, 41.7). The 1-year survival rate was 15%. Grade 3/4 toxicities were more frequent in the 45 mg dose level group (87% vs. 43%, p=0.002). These included fatigue, hypertension, pulmonary embolism, angioedema, and reversible posterior leukoencephalopathy. Median OS was superior in patients who developed ≥grade 3 hypertension (8.5 vs. 4.1 months, p=0.024). CONCLUSION: This trial did not meet its pre-specified response endpoint. A higher cediranib dose level was associated with improved disease control, but this dose was poorly tolerated.
Authors: Steven Chuan-Hao Kao; Rozelle Harvie; Florian Paturi; Robyn Taylor; Ross Davey; Rick Abraham; Stephen Clarke; Gavin Marx; Martin Cullen; Zoltan Kerestes; Nick Pavlakis Journal: Lung Cancer Date: 2011-07-16 Impact factor: 5.705
Authors: Sarita Dubey; Pasi A Jänne; Lee Krug; Herbert Pang; Xiaofei Wang; Robin Heinze; Colleen Watt; Jeff Crawford; Robert Kratzke; Everett Vokes; Hedy Lee Kindler Journal: J Thorac Oncol Date: 2010-10 Impact factor: 15.609
Authors: Thierry Jahan; Lin Gu; Robert Kratzke; Arkadiusz Dudek; Gregory A Otterson; Xiaofei Wang; Mark Green; Everett E Vokes; Hedy Lee Kindler Journal: Lung Cancer Date: 2011-12-22 Impact factor: 5.705
Authors: Paul Baas; Willem Boogerd; Otilia Dalesio; Annebeth Haringhuizen; Frank Custers; Nico van Zandwijk Journal: Lung Cancer Date: 2004-12-15 Impact factor: 5.705
Authors: Joachim Drevs; Patrizia Siegert; Michael Medinger; Klaus Mross; Ralph Strecker; Ute Zirrgiebel; Jan Harder; Hubert Blum; Jane Robertson; Juliane M Jürgensmeier; Thomas A Puchalski; Helen Young; Owain Saunders; Clemens Unger Journal: J Clin Oncol Date: 2007-07-20 Impact factor: 44.544
Authors: Sivakumar Loganathan; Rajani Kanteti; Shahid S Siddiqui; Essam El-Hashani; Maria Tretiakova; Hari Vigneswaran; Gustavo Cervantes; Viswanathan Natarajan; Aliya N Husain; Everett E Vokes; Hedy L Kindler; Ravi Salgia Journal: J Carcinog Date: 2011-03-03
Authors: Christina A K Kim; Julie Price-Hiller; Quincy S Chu; Keith Tankel; Ron Hennig; Michael B Sawyer; Jennifer L Spratlin Journal: Invest New Drugs Date: 2014-05-23 Impact factor: 3.850
Authors: S Sahebjam; P L Bedard; V Castonguay; Z Chen; M Reedijk; G Liu; B Cohen; W-J Zhang; B Clarke; T Zhang; S Kamel-Reid; H Chen; S P Ivy; A R A Razak; A M Oza; E X Chen; H W Hirte; A McGarrity; L Wang; L L Siu; S J Hotte Journal: Br J Cancer Date: 2013-07-18 Impact factor: 7.640